ReWalk Robotics

LFWD

Market cap $19.7M

Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic disease

Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript

Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $5.52 per share a year ago.

Oramed  strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery ™ biomed technology , with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 million stroke survivors Quarterly operating cash burn reduced by 33% year-over-year, reflecting improved operational efficiencies and working capital management Continued improvements in o perating expenses and cash utilization as company prepares to scale neurorehabilit ati on products volume Conference call scheduled for 8:30 AM ET today HUDSON, Mass.

HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the Company will report its first quarter 2026 financial results before the U.S. markets open on Friday, May 15, 2026.

Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018 , spanning broad patient profiles and bone health conditions Findings reinforce safety profile and support expanded adoption of ReWalk for spinal c ord injury mobility Lifeward CEO Mark Gr ant addressed the 53 rd ASIA Annual Scientific Meeting audience with a speech regarding Lifeward and its vision for restoring full function to people living with spinal cord injuries HUDSON, Mass., and YOKNEAM ILLIT, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Lifeward Ltd. (LFWD) Q4 2025 Earnings Call Transcript

Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction r eceives s hareholder a pproval ; Lifeward g ain s n ew o ral p rotein d elivery t echnology p latform Lifeward a lready e xecuting n ew s trategy t hrough a cquisition of p owered u pper- b ody e xoskeleton t echnology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.